Securities code: 688506 Securities abbreviation: Baili Tianheng Announcement No.: 2025-025

Sichuan Baili Tianheng Pharmaceutical Co., Ltd

Announcement on the change of the continuous supervision agency and sponsor representative

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

According to the Reply on Agreeing to the Registration of the Initial Public Offering of Shares of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. issued by the China Securities Regulatory Commission (Zheng Jian Xu Xu [2022] No. 2969) and the Notice on the Listing and Trading of RMB Ordinary Shares of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on the Science and Technology Innovation Board ([2023] No. 1) issued by the Shanghai Stock Exchange, Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was approved for the first time

The company made a public offering of shares and was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on January 6, 2023. Company hired

SDIC Securities Co., Ltd. (hereinafter referred to as "SDIC Securities", formerly known as "Essence Securities Co., Ltd.") served as the sponsor of the company's initial public offering and listing, and SDIC Securities continued to supervise the company

Originally scheduled to run until December 31, 2026.

The company held the 19th meeting of the 4th board of directors and the 17th meeting of the 4th board of supervisors on March 9, 2025

The meeting, the first extraordinary general meeting of shareholders in 2025 was held on March 25, 2025, and the proposal was deliberated and approved

Proposal for the issuance of A shares by a specific target (hereinafter referred to as the "Offering"). According to the needs of this issuance, the company recently signed a sponsorship agreement with CITIC Securities Co., Ltd. (hereinafter referred to as "CITIC Securities") to appoint CITIC Securities as the sponsor of this offering.

According to the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing and other relevant provisions, if the company engages a sponsor institution for the issuance of securities again, it shall terminate the sponsorship agreement with the original sponsor institution, and the sponsor institution hired separately shall complete the continuous supervision work that has not been completed by the original sponsor institution. In view of the fact that the company has signed a sponsorship agreement with CITIC Securities, SDIC Securities will no longer perform the corresponding continuous supervision duties, and the unfinished continuous supervision work of SDIC Securities will be undertaken by CITIC Securities. CITIC Securities has appointed Mr. Yang Qin and Mr. Chen Wei (resume attached) as the sponsor representatives of the issuance, specifically responsible for the sponsorship and continuous supervision of the company's issuance.

The company would like to express its heartfelt thanks to SDIC Securities and its project team for their work during the company's initial public offering and continuous supervision.

The announcement is hereby made.

Board of Directors of Sichuan Baili Tianheng Pharmaceutical Co., Ltd

March 29, 2025

Annex:

Yang Qin: The sponsor representative of this project, he is currently the director of the medical and health industry group of the Investment Banking Committee of CITIC Securities. He has presided over or participated in projects such as Allist's IPO on the Science and Technology Innovation Board, Navitas Technology Science and Technology Innovation Board IPO, Yahong Pharmaceutical Science and Technology Innovation Board IPO, Yifang Biotech Science and Technology Innovation Board IPO, Shangji CNC Motherboard IPO, Laimei Pharmaceutical Non-public Offering and other projects.

Chen Wei: The sponsor representative of this project, he is currently the vice president of the medical and health industry group of the investment banking committee of CITIC Securities. The projects he has presided over or participated in include: Allist Science and Technology Innovation Board IPO, Yahong Pharmaceutical Science and Technology Innovation Board IPO, and Sinopharm Present

On behalf of 2022 non-public, 2020 non-public, 2019 convertible bonds and other projects.